在患有阿尔茨海默氏症的患者中,神经精神病症状和微质激活
Cristiano Schaffer Aguzzoli1,2,3, Pâmela C L Ferreira1,4, Guilherme Povala1
1Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
JAMA network open
|November 27, 2023
概括
微质激活与阿尔茨海默病中的神经精神症状有关,这表明它是潜在的生物标志物. 针对β-粉样蛋白和微质都可能有助于缓解这些衰弱的症状.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物标志物发现发现
背景情况:
- 神经精神症状在阿尔茨海默氏症 (AD) 中是常见的和衰弱的.
- 了解这些症状的生物学基础对于开发有效的生物标志物和治疗方法至关重要.
- 质标记物,特别是微质激活,越来越多地被认为是它们在神经退行过程中的作用.
研究的目的:
- 研究质标记物,特别是微质激活,与阿尔茨海默病连续体中个体神经精神病症状的存在和严重程度之间的关联.
- 探索微质激活作为AD神经精神病症状的生物标志物的潜力.
主要方法:
- 进行了一项涉及AD连续的109名参与者的横截面研究.
- 参与者通过使用神经精神病学库存问卷 (NPI-Q) 对神经精神病症状进行了评估.
- 使用正子发射断层扫描 (PET) 图像测量微质激活 ([11C]PBR28 PET),粉样蛋白-β ([18F]AZD4694 PET) 和陶 ([18F]MK6240 PET).
主要成果:
- 额叶,叶和叶皮层中的微质激活与神经精神症状的整体严重程度 (NPI-Q评分) 有显著的关联.
- 刺激性,一种特定的神经精神症状,最强烈地与大脑微质激活的存在有关.
- 微质相关的易怒与研究伙伴报告的痛苦增加相关 (NPI-Q痛苦得分).
结论:
- 微质激活与阿尔茨海默病患者的神经精神症状有关,表明其作为生物标志物的潜力.
- 这些研究结果表明,针对β-粉样蛋白和微质细胞的疗法可能有助于在AD中控制神经精神病症状.
- 对质激活通路的进一步研究可能会导致AD相关的神经精神疾病的新疗法策略.
更多相关视频
09:12Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
15.9K
12:48In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma
Published on: May 11, 2015
10.6K
相关概念视频
Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
